Skip to content
Search

Latest Stories

Medicine supply shortages now worse than ever, says Janet Morrison

Medicine supply shortages now worse than ever, says Janet Morrison

The number of products in short supply has doubled in the past two years,  affecting treatments for various conditions 

Pharmacists have expressed concerns about severe shortage of medicines in the NHS, which is putting lives at risk.


Unpublished figures obtained by The Guardian have shown that the number of products in short supply has doubled in the past two years.

The report highlighted short supply of treatments for various conditions including epileptic seizures, cancer, schizophrenia, and diabetes.

A few days back, the Department of Health and Social Care (DHSC) informed healthcare professionals that supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are used to treat type 2 diabetes, continues to be limited and is not likely to return to normal until at least the end of 2024.

Clinicians were instructed to only prescribe the antidiabetes drugs for licensed indications, and avoid prescribing for weight loss to conserve existing stock for patients with T2DM.

In November 2023, the British Generic Manufacturers Association (BGMA) had revealed that 111 products were facing supply issues, the highest on record and more than double since the start of 2022.

In a statement shared with the newspaper, Janet Morrison, CEO of Community Pharmacy England (CPE) said: “Pharmacy teams have been struggling to get hold of prescription medicines for many months but the problem is now worse than ever.”

“It has become worryingly normal to see hundreds of medicines affected by pricing and other issues every month, with problems now a daily occurrence for pharmacies.

“The instability is putting operational pressures on pharmacy teams, financial pressures on pharmacy businesses, and for patients it means worrying delays.”

Last year, CPE surveyed people working in pharmacies and 87 per cent of the respondents said that their patients’ health was being put a risk due to medicine supply issues.

Janet cited a combination of factors for medicines supply issues, including Brexit, the ongoing war in Ukraine, the impact of the Covid-19 pandemic, and broader economic instability.

“The NHS and Government need to step in to stabilise the UK medicines supply chain,” she stated.

To address the problem, Janet suggested a “full strategic review of medicines supply in England” and to empower pharmacists to use their knowledge to make “simple changes to medicines where this can speed up supply of medicines safely.”

“This step will help to alleviate this critical situation for both pharmacies and the communities they serve,” she added.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less